Tao Zhang
Clinical trials sponsored by Tao Zhang, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simple supplement boost rectal cancer treatment? Results expected Dec 2026 (estimated)
- New hope for Hard-to-Treat colorectal cancer? drug combo trial launches Results expected Jan 2027 (estimated)
- New triple therapy targets hard-to-treat liver metastases in colorectal cancer Results expected Aug 2027 (estimated)
-
New hope for Hard-to-Treat colorectal cancer? drug combo trial launches
Disease control Recruiting nowThis phase 2 trial is testing whether combining the drug pirfenidone with an immunotherapy (PD-1 inhibitor), and possibly adding focused radiation, can help people with advanced colorectal cancer that hasn't responded to standard treatments. The study will enroll 48 adults aged 1…
Phase 2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to boost rectal cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (HLX10) to standard chemotherapy and radiation before surgery improves outcomes for people with locally advanced rectal cancer. It compares short-course versus long-course radiation, both followed by immunotherapy and …
Phase 3 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a simple supplement boost rectal cancer treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether adding a dietary supplement called β-hydroxybutyrate to a standard treatment plan (short-course radiotherapy, immunotherapy, and chemotherapy) can improve outcomes for people with locally advanced rectal cancer. The study will enroll 25 adult…
Phase 2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC